Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Candesartan in Heart Fail. Assess. of Reduction in Mortality & Morbidity. Candesartan in Patients With Heart Failure Who Are ACE Inhibitor Intolerant and Have Depressed Left Ventricular Systolic Function

NCT00634400 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00634400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00634400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Candesartan in Heart Fail. Assess. of Reduction in Mortality & Morbidity. Candesartan in Patients With Heart Failure Who Are ACE Inhibitor Intolerant and Have Depressed Left Ventricular Systolic Function
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
March 31, 1999
Completion date
May 31, 2003
Enrollment
6,268 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

congestive heart failure